Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
cardiometabolic diseases
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "cardiometabolic diseases" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
APE-PLD (VU533) activator is a potent NAPE-PLD activator with an EC50 value of 0.30 µM. NAPE-PLD activator (VU533) can enhance NAPE-PLD activity and increase efferocytosis by macrophages. NAPE-PLD activator (VU533) can be used for cardiometabolic diseases research .
Cat. No.: HY-P4153
CAS No.: 2407527-16-4
Synonyms: MK-0616 chloride
Target:
Research Areas:
Synonyms: N-Behenoyl-D-erythro-sphingosine; C22-Ceramide; Cer d18:1/22:0
Target:
Research Areas:
C22-Ceramide (d18:1/22:0) (N-Behenoyl-D-erythro-sphingosine) is an ultra-long-chain ceramide containing a C22:0 behenoyl acyl chain. C22-Ceramide can be glycosylated via CGT-3 to form C22 glucosylceramide (C22 GlcCer), which in turn maintains clathrin membrane localization and lysosomal homeostasis, inhibits TOR signaling and promotes SKN-1 activation, thereby enhancing oxidative stress resistance and extending the lifespan of C. elegans. C22-Ceramide can be used in research on cardiometabolic diseases such as type 2 diabetes, obesity, dyslipidemia, coronary artery disease and thin-cap fibroatheroma (TCFA), as well as oxidative stress and aging-related studies .
Cat. No.: HY-155157
Purity: 98.66%
Target:
Research Areas:
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .
Synonyms: SLPC; 18:0-18:2 PC
Target:
Category:
Cardiovascular Disease Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields
Target:
Target:
Research Areas:
VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
Cat. No.: HY-147751
CAS No.: 1965244-85-2
Target:
Research Areas:
APJ receptor agonist 6 (compound 9) is a potent APJ (apelin receptor) agonist, with Ki of 1.3 μM. APJ receptor agonist 6 has EC50 values of 0.070 , 0.097, and 0.063 μM for calcium, cAMP, and β-arrestin, respectively .
Cat. No.: HY-P11321A
Synonyms: acyl-GIP hydrochloride
Target:
Research Areas:
Cat. No.: HY-P11321
Synonyms: acyl-GIP
Target:
Research Areas:
Cat. No.: HY-155156
Purity: 99.46%
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .
Cat. No.: HY-174805
CAS No.: 2411677-11-5
Target:
Research Areas:
THRβ receptor agonist-2 (Example 7-4) is a THRβ receptor agonist. THRβ receptor agonist-2 can be used for research of liver disorder or a cardiometabolic disease .
Cat. No.: HY-130245A
CAS No.: 2216703-12-5
Research Areas:
(R,R)-PCSK9 degrader 1 is an isomer of PCSK9 degrader 1 (HY-130245). (R,R)-PCSK9 degrader 1 is a HyT-like PCSK9 degrader (IC50 of 655.4 nM) , and its PCSK9-binding site does not interfere with the binding of PCSK9 to LDL receptor. (R,R)-PCSK9 degrader 1 can be used in the research of atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, and related cardiovascular and cardiometabolic diseases .
Cat. No.: HY-169334
Target:
Research Areas:
BDK-IN-1 (compound (-)-43) is a BDK inhibitor with the IC50 of 0.23 μM and the max inhibition of 90%. BDK-IN-1 decreases the level of phospho-E1 and can be used for study of cardiometabolic diseases .
Cat. No.: HY-L263
89 compounds
Energy metabolism is the most fundamental biochemical process in living organisms, encompassing glycolysis, the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid oxidation. These core pathways directly regulate cell survival, proliferation, differentiation, and apoptosis. Dysregulation of energy metabolism is closely linked to major diseases including cancer, diabetes, obesity, cardiovascular diseases, neurodegenerative disorders, and ischemia‑reperfusion injury. Targeting these metabolic pathways has become a frontier in drug discovery and mechanistic research.
The MCE Energy Metabolite Compound Library features 89 structurally defined small‑molecule compounds. It covers energy substrates, pathway intermediates, coenzymes and redox carriers, nucleotide derivatives, and microenvironmental modulators. This library is applicable to research areas including tumor metabolism, insulin resistance, mitochondrial dysfunction, oxidative stress, neuroprotection, and cardiometabolic diseases, providing a high‑quality tool for mechanistic studies, biomarker discovery, and high‑throughput drug screening.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
